Menu

Cancers Relapse by Feeding Off Immune Signals

In mice, the tumor cells are able to thwart the immune response that would kill them—but immunotherapy prevented the return of melanoma.

Oct 16, 2017
Shawna Williams

ISTOCK; SELVANEGRAAfter a seemingly successful cancer treatment, a few hearty cancer cells can remain in patients’ bodies, a dangerous persistence known as minimal residual disease (MRD). A new study, published today (October 16) in Cancer Immunology Research, finds that these cells can later respond to signals from the body’s immune system and form new tumors—and that during this recurrence, they use signals of their own to blind immune cells to their presence.

The researchers find that treating mice with immunotherapies takes the blindfolds off the immune system and enables it to fend off the tumors.

“It is becoming increasingly clear that the immune system is at the core of the puzzle of how we can treat cancer more effectively,” says study coauthor Kevin Harrington of the Institute for Cancer Research in London in a statement. “This fascinating new study helps explain why sometimes a patient’s immune system can be effective against cancer cells while at other times it is not. It also shows there is a lot more to learn about the nature of those cancer cells that lie dormant as a way of resisting the killing effects of cancer treatments.”

Using genetically engineered mice injected with melanoma cells, Harrington and colleagues found that immune cell signals associated with a response to trauma or infection, namely VEGF and TNFα, can promote cancer growth in MRD.

As the cells begin growing into new tumors, they induce nearby natural killer cells to secrete more of a signal called IL6 but less of another, IFNγ. This reaction in turn inhibits both those natural killer cells and T cells from detecting and fighting the cancer, the authors write in the study.

In addition, the team found, the surfaces of the resurgent cancer cells had high levels of the molecule PD-L1, which signals T cells not to attack. But when the mice were treated with inhibitors of either PD-1 (the T-cell receptor that interacts with PD-L1), TNFα, or natural killer cells themselves, cancer recurrence took longer or didn’t occur at all.

“The immune system goes from keeping cancer cells in check to awakening and feeding residual cells, while turning a blind eye to their growth,” says coauthor Alan Melcher of the Institute for Cancer Research, in a statement. “Excitingly, many of the methods employed by treatment-resistant tumours to re-grow and hide from the immune system can be blocked using existing immunotherapies. This idea is, in fact, supported by emerging data from clinical trials, showing that immunotherapies can reduce the risk of cancers coming back.”

September 2018

The Muscle Issue

The dynamic tissue reveals its secrets

Marketplace

Sponsored Product Updates

StemExpress LeukopakâNow Available in Frozen Format

StemExpress LeukopakâNow Available in Frozen Format

StemExpress, a Folsom, California based leading supplier of human biospecimens, announces the release of frozen Peripheral Blood Leukopaks. Leukopaks provide an enriched source of peripheral blood mononuclear cells (PBMCs) with low granulocyte and red blood cells that can be used in a variety of downstream cell-based applications.

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

New Antifade Mounting Media from Vector Laboratories Enhances Immunofluorescence Applications

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow.

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Best Practices for Sample Preparation and Lipid Extraction from Various Samples

Download this white paper from Bertin Technologies to learn how to extract and analyze lipid samples from various models!

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Launches CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin for Process Protein Purification

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of two new chromatography media for process protein purification: CHT Ceramic Hydroxyapatite XT Media and Nuvia HP-Q Resin.